A randomized placebo-controlled trial of Erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. - Shepherd,F.A.; Pereira,J.; Ciuleanu,T.E. (Proc ASCO, 2004)